Trials / Withdrawn
WithdrawnNCT01557647
Safety and Efficacy of Inhaled Treprostinil in Patients With PAH
Inhaled Treprostinil for the Treatment of Pulmonary Arterial Hypertension: A Phase III, International, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Event-Driven Study to Evaluate the Safety and Efficacy of Inhaled Treprostinil.
- Status
- Withdrawn
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- United Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
To evaluate the effect of inhaled treprostinil compared to placebo on exercise capacity and time to clinical worsening.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Inhaled treprostinil | 0.6mg/mL treprostinil for inhalation solution. Titrated up to 12 breaths QID. |
| DRUG | Placebo | placebo inhalation solution |
Timeline
- Start date
- 2012-06-01
- Primary completion
- 2015-12-01
- Completion
- 2016-06-01
- First posted
- 2012-03-19
- Last updated
- 2012-03-26
Source: ClinicalTrials.gov record NCT01557647. Inclusion in this directory is not an endorsement.